Abstracts tagged "Raynaud’s"

Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Ashima Makol¹, Alicia Hinze², Rachel Giblon¹, Yasser Radwan³, Tina Gunderson⁴, David Liedl¹, Kenneth J. Warrington⁴, Cynthia Crowson⁵ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic/ Michigan State University, Lansing, MI, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…
Abstract Number: 1541 • ACR Convergence 2022
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
Michael Hughes¹, Stefano Di Donato², Klodian Gjeloshi³, Giuseppina Abignano⁴, Fiammetta Danzo³, Giovanni Lettieri G⁴, Enrico De Lorenzis², Dominic Bertham⁵, Philip O’Connor², Olga Kubassova⁶ and Francesco Del Galdo², ¹Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ³University of Campania ‘‘Luigi Vanvitelli’’, Napoli, Italy, ⁴Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Image Analysis Group, London, United Kingdom
Background/Purpose: Fibroproliferative vasculopathy in systemic sclerosis (SSc) is caused by neointima proliferation is a key pathologic feature of SSc which results in arterial vessel narrowing…
Abstract Number: 1773 • ACR Convergence 2022
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Rashmi Dhital¹, Monica Guma², Thuthiri Lwin³, Amar Suwal⁴ and Brian Pedersen¹, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³University of California San Diego, San Diego, CA, ⁴Reading Hospital, Tower Health, Reading, PA
Background/Purpose: The prevalence of Raynaud's phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes…
Abstract Number: 0412 • ACR Convergence 2021
Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Ashima Makol¹, Caitrin Coffey¹, Tina Gunderson¹, Alicia Hinze¹, Yasser Radwan², Cynthia Crowson³, David Liedl¹, Kenneth Warrington¹ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, ²Michigan State University, Lansing, MI, ³Mayo Clinic, Eyota, MN
Background/Purpose: To study the prevalence, anatomical distribution, clinical correlates and outcomes of macrovascular disease (MVD) on duplex ultrasound (US) of the upper extremity in Systemic…
Abstract Number: 0923 • ACR Convergence 2020
Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?
Martina Plešivčnik-Novljan¹, Daša Šuput Skvarča¹, Ajda Jezernik¹, Saša Čučnik¹, Žiga Rotar¹ and Alojzija Hocevar², ¹University Medical Center Ljubljana, Ljubljana, Ljubljana, Slovenia, ²University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Different criteria aiding the diagnosis of Raynaud’s phenomenon (RP) have been proposed. Wigley’s “RP criteria 2002”, defined RP by history of cold sensitivity, accompanied…
Abstract Number: 1377 • ACR Convergence 2020
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Tracy Frech¹, Maureen Murtaugh¹, Megan Amuan² and Mary Jo Pugh¹, ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The purpose of this project was to describe Raynaud's phenomenon (RP), very early diagnosis of systemic sclerosis (VEDOSS), and systemic sclerosis (SSc) in Veterans…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].